Longevity Market: $8 Trillion Opportunity for Entrepreneurs & Investors by 2030

The health and wellness sector is experiencing a significant shift, moving beyond simply extending lifespan to prioritizing healthspan – the years lived in good health. This evolution is driving a market projected to reach $8 trillion by 2030, according to a UBS report from March 2025, surpassing even the anticipated growth of artificial intelligence, currently projected at $1.16 trillion by 2027.

This isn’t merely a consumer trend. it’s a structural change impacting healthcare systems, financial markets and investment strategies. The focus on healthspan represents a compelling opportunity for founders and venture capitalists, but success will hinge on understanding the nuances of this emerging landscape.

The Gap Between Living Longer and Living Well

While global lifespans have increased, the quality of those added years hasn’t kept pace. Data from the World Health Organization (2024) reveals a roughly decade-long gap between average global lifespan (71.4 years) and healthspan (61.9 years). This means people are living longer, but spending a significant portion of their later years managing chronic disease. Scientific American confirmed this trend in 2025, noting that improvements in lifespan haven’t translated into comparable gains in healthspan.

By 2050, the global population over 60 is expected to exceed 2 billion. In the U.S., adults 65 and older are projected to comprise nearly a quarter of the population within the next decade. This demographic shift isn’t a niche market; it’s a reshaping of the economic landscape, impacting labor markets, financial systems, and consumer spending patterns, as highlighted in the World Economic Forum’s 2025 report on future-proofing the longevity economy.

Prevention: A Novel Economic Driver in Healthcare

The rising cost of chronic disease is driving a fundamental shift towards preventative healthcare. In the U.S., where chronic illnesses account for the majority of healthcare spending, consumers are increasingly willing to invest in solutions that promote metabolic health, mobility, cognitive function, and overall resilience before the onset of serious illness. The rapid adoption of GLP-1 therapies – medications initially for diabetes, now widely used for weight loss – exemplifies this trend, reframing metabolic health as something modifiable and driving investment towards preventative models.

UBS projects annual growth of 5% to 7% in sectors tied to healthspan, including active and medical nutrition, supplements, and consumer health and wellness technology. Adjacent industries, such as beauty, hospitality, and travel, are also experiencing growth (4.5% to 6.3% compound annual growth rate) as they adapt their offerings to cater to a longevity-focused lifestyle. This isn’t a fleeting trend, but a broad reorientation of consumer spending.

Strategic Positioning by Corporate Incumbents

Large corporations are already making strategic moves to capitalize on this shift. Unilever, for example, has expanded its wellness portfolio through acquisitions of companies like Onnit and OLLY, signaling a commitment to the preventative health and longevity market. This activity isn’t just about consumer demand; it indicates potential exit pathways for venture-backed companies as strategic buyers seek to build comprehensive longevity-aligned portfolios. Healthspan is becoming integrated into mainstream corporate strategy, moving beyond specialist biotech circles.

The Importance of Evidence-Based Innovation

As capital flows into the longevity sector, scientific credibility will be paramount. Businesses built on evidence-based innovation, clinical validation, and measurable outcomes will be best positioned for long-term success. Founders need to prioritize collaboration with researchers, scientists, and practitioners, embedding data collection and real-world validation into their business models from the outset. In a space prone to hype and speculation, rigorous scientific backing will be a key competitive advantage.

From Fringe to Institutional: The Maturing Longevity Market

The longevity conversation is gaining mainstream acceptance. The 2023 Global Healthspan Summit in Riyadh marked a significant milestone, bringing together founders, investors, and researchers to shape the future of the sector. Discussions that were once relegated to the fringes of biotech and wellness are now central to capital allocation and long-term healthcare strategy. Longevity and preventative health were also prominent themes at recent J.P. Morgan Healthcare Conferences, further demonstrating the sector’s growing influence within mainstream healthcare investing.

Investment in the longevity space more than doubled in 2024, reaching approximately $8.5 billion across 325 deals. Roughly one-third of this funding came from later-stage venture capital, indicating increasing confidence from institutional investors. With the market projected to reach $8 trillion by 2030, longevity is no longer a niche investment; it represents a fundamental shift in how ageing populations, healthcare systems, and capital markets approach value creation.

For founders and VCs operating in health, longevity, wellness, or consumer technology, this convergence of scale and impact presents a rare opportunity. The goal isn’t simply to extend life, but to redefine how those added years are lived – and to build businesses that facilitate a healthier, more fulfilling future.